Automated Insulin Delivery
Advances in continuous glucose monitoring (CGM) has led to a paradigm shift in the management of type 1 diabetes. The developments have enabled the automation of insulin delivery, where an algorithm determines the insulin delivery rate in response to the CGM values. There are numerous automated insulin delivery (AID) systems under development, some of which are becoming fully-fledged and mature, following which the future designs may incorporate additional hormones and several inputs, such as the activity level or monitoring other diabetic symptoms. The future CGM devices must show to be sufficiently accurate to be safely incorporated into AID.
The purpose of the whitepaper is to showcase and generate awareness among the readers about how the AIDs are helping in the diabetes management, the recent achievements in AID development, the key players and the market insights. AID is becoming a reality, and many biotechnology companies are taking a step forward to do the behavioural analysis and scrutinize the patient lifestyle.
Through this whitepaper, DelveInsight has raised several interesting insights about the Automated Insulin Delivery systems from bench to clinical practice, various innovations and trends, and also highlighted several approved and upcoming AID systems, improvising the patient experience and satisfaction.